摘要
目的:探讨在快速现场评价(ROSE)与径向支气管内超声(R-EBUS)辅助下经支气管冷冻活检(TBCB)在弥漫性肺疾病(DLD)诊断中的可行性和安全性。方法:收集2019年6月至2021年9月宁波市医疗中心李惠利医院行TBCB的DLD患者,记录临床特征、病理类型、活检特征和并发症,分析TBCB在DLD诊断中的可行性和安全性。结果:共收集52例患者,其中男20例,女32例,年龄(54.0±13.2)岁;总共活检182次,人均(3.50±1.00)次;标本大小6~30 mm^(2),平均(13.69±4.72)mm^(2)。参照2013美国胸科学会/欧洲呼吸病学会对间质性肺疾病分类标准,已知病因26例(50.00%),特发性间质性肺炎13例(25.00%);肉芽肿性病变4例(7.69%),其他类型9例(17.31%)。在并发症方面,没有或极少量出血20例,轻度出血21例,中度出血11例,重度出血0例;气胸2例。急性左心衰1例,低氧血症1例。术后中位住院时间6(1.00,6.00)d。结论:联合应用ROSE与R-EBUS于TBCB在DLD诊断中具有一定的可行性和安全性。
Objective:To investigate the feasibility and safety of transbronchial cryobiopsy(TBCB)in the diagnosis of diffuse lung diseases(DLD)with assistance of Rapid On-Site Evaluation(ROSE)and Radial-endobronchial ultrasound(R-EBUS).Methods:Patients with diffuse lung disease who underwent TBCB from June 2019 to September 2021 were enrolled and their clinical characteristics,pathological types,biopsy characteristics and complications were recorded.Results:A total of 52 patients were included in the study,20 males and 32 females,with a mean age of(54.0±13.2)years;a total of 182 cryobiopsies,(3.50±1.00)cryobiopsies per patient;the mean size of tissues was(13.69±4.72)mm^(2),ranging 6-30 mm^(2).According to the 2013 ATS/ERS classification standard for the interstitial lung diseases,there were 26 cases of known etiology(50.00%),13 cases of idiopathic interstitial pneumonia(25.00%),4 case of granulomatous lesions(7.69%)and 9 cases of other types(17.31%).In terms of complications,none or minimal bleeding occurred in 20 patients,mild bleeding in 21 patients,moderate bleeding in 11 patients.No severe bleeding occurred.Pneumothorax occurred in 2 patients,acute left heart failure in 1 patient and hypoxemia in 1 patient.The median post-TBCB hospital day was 6(1.00,6.00)days.Conclusion:The combined application of ROSE and R-EBUS in TBCB is feasible and safe in the diagnosis of DLD.
作者
陈伟庄
李优
王辉
周莹艳
王国安
沈世茉
陈金平
吴仕波
吴宏成
CHEN Weizhuang;LI You;WANG Hui;ZHOU Yingyan;WANG Guoan;SHEN Shimo;CHEN Jinping;WU Shibo;WU Hongcheng(Department of Pulmonary and Critical Care Medicine,Ningbo Medical Treatment Center Li Huili Hospital,Ningbo 315040,China;Ningbo Diagnostic Pathology Center,Ningbo 315021,China)
出处
《温州医科大学学报》
2022年第2期132-138,共7页
Journal of Wenzhou Medical University
